Stock listing
1IY0 Stock Price, News, Filings & Events — Monopar Therapeutics Inc.
Selected listing: 1IY0 · TRADEGATE · EUR · DE
This page tracks Monopar Therapeutics Inc.'s 1IY0:TRADEGATE listing on TRADEGATE in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 1IY0:TRADEGATE. 1IY0:TRADEGATE is the stock-level entry point for investors researching Monopar Therapeutics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- 1IY0:TRADEGATE
- Asset type
- Stock
- Market cap
- $740.1M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- TRADEGATE
- Currency
- EUR
Monopar Therapeutics Inc. 1IY0:TRADEGATE stock context
This page tracks Monopar Therapeutics Inc.'s 1IY0:TRADEGATE listing on TRADEGATE in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 1IY0:TRADEGATE. 1IY0:TRADEGATE is the stock-level entry point for investors researching Monopar Therapeutics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Monopar Therapeutics Inc.
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AAS...
August 19, 2026
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 13, 2026
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 12, 2026
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
July 22, 2026
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Comm...
July 20, 2026
Research Monopar Therapeutics Inc.
Monopar Therapeutics Inc. investor report
Review AI stock analysis and investor report context for 1IY0:TRADEGATE.
Monopar Therapeutics Inc. company profile
View the public company page for Monopar Therapeutics Inc. on 6ix.
Monopar Therapeutics Inc. news
Read company news and market updates connected to Monopar Therapeutics Inc..
Monopar Therapeutics Inc. investor events
Find investor webinars, events, and replay context for Monopar Therapeutics Inc..
Alternate listings
MNPR:NASDAQ
US · USD
Alternate listing for Monopar Therapeutics Inc.; the primary context on this page is 1IY0:TRADEGATE.
A40JML:LSX
DE · EUR
Alternate listing for Monopar Therapeutics Inc.; the primary context on this page is 1IY0:TRADEGATE.
1IY0:GETTEX
DE · EUR
Alternate listing for Monopar Therapeutics Inc.; the primary context on this page is 1IY0:TRADEGATE.
A40JML:LS
DE · EUR
Alternate listing for Monopar Therapeutics Inc.; the primary context on this page is 1IY0:TRADEGATE.
MNPR:BOATS
US · USD
Alternate listing for Monopar Therapeutics Inc.; the primary context on this page is 1IY0:TRADEGATE.
1IY0:FWB
DE · EUR
Alternate listing for Monopar Therapeutics Inc.; the primary context on this page is 1IY0:TRADEGATE.
1IY0:MUN
DE · EUR
Alternate listing for Monopar Therapeutics Inc.; the primary context on this page is 1IY0:TRADEGATE.
1IY0:SWB
DE · EUR
Alternate listing for Monopar Therapeutics Inc.; the primary context on this page is 1IY0:TRADEGATE.